AR and prostate adenocarcinoma: To further explore the potency and specificity of 1ae and EPI-001 on the AR-driven transcriptional program, we used RNA sequencing (RNA-seq) on LNCaP prostate adenocarcinoma cells after treatment with approximately IC10 and IC50 doses of the compounds for 6 or 24 h (Fig. 6a–c and Extended Data Fig. 7a,b).